The new drug, Kisunla, has the potential to be a blockbuster for the company and generate billions in revenue. But despite ...
Alzheimer’s patients can temporarily lessen their symptoms with a recent FDA-approved drug that removes amyloid, or protein, ...
It's not a cure-- but it is a step in the right direction.This month-- a new medication for alzheimer's, called 'kinsul'a, ...
The Food and Drug Administration (FDA) recently approved a new drug from Eli Lilly to treat Alzheimer’s disease. Called ...
The Food and Drug Administration approved a new Eli Lilly drug this month that treats Alzheimer's disease. Kisunla is an IV ...
The FDA approved donanemab, which will be sold under the brand name Kisunla. The new drug helps slow decline in Alzheimer's patients with mild cognitive impairment.
Analyst Andrew Fein of H.C. Wainwright maintained a Buy rating on Vigil Neuroscience Inc (VIGL – Research Report), reducing the price ...
LGVN READ THE FULL LGVN RESEARCH REPORT Longeveron (NASDAQ:LGVN) announced that its primary treatment, Lomecel-B, has been granted Fast Track designation by the FDA only a week after being granted ...
The FDA approved Kisunla, known chemically as donanemab ... aren’t yet setup to prescribe the new plaque-targeting Alzheimer's drugs. First, doctors need to confirm that patients with dementia ...
The Food and Drug Administration recently approved Kisunla as a treatment for early symptomatic Alzheimer's disease ... Eli Lilly's non-move following the FDA's decision is that it wasn't unexpected.
The US Food and Drug Administration (FDA) has approved Swiss company Positrigo’s NeuroLF brain positron emission tomography (PET) system. The NeuroLF ultra-compact system is designed to aid in the ...